Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About QDEL Interactive Breakdown Better Bets vs. QDEL Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

QuidelOrtho (QDEL)

Market Price (10/23/2025): $29.79 | Market Cap: $2.0 Bil
Sector: Health Care | Industry: Health Care Supplies

QuidelOrtho (QDEL)

Market Price (10/23/2025): $29.79
Market Cap: $2.0 Bil
Sector: Health Care
Industry: Health Care Supplies

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34%		 Weak multi-year price returns
2Y Excs Rtn is -112%, 3Y Excs Rtn is -144%		 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 131%
1  Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%		 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%, Rev Chg QQuarterly Revenue Change % is -3.6%
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28%
0 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -34%
1 Weak multi-year price returns
2Y Excs Rtn is -112%, 3Y Excs Rtn is -144%
2 Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 13%
3 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 131%
4 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.3%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%, Rev Chg QQuarterly Revenue Change % is -3.6%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28%

Market Valuation & Key Metrics

QDELS&P 500
REVENUE GROWTHVERY POOR
Rev LTM ($ Bil)2.7
Rev Chg Q-3.6%6.1%
Rev Chg LTM-3.3%5.2%
Rev Chg 3Y Avg0.3%5.4%
PROFITABILITYVERY POOR
Op Inc LTM ($ Bil)0.1
CFO LTM ($ Bil)0.2
Net Inc LTM ($ Bil)-0.5
Op Mgn LTM4.2%18.6%
CFO/Rev LTM7.3%20.4%
Net Inc Mgn-17.0%12.7%
VALUATIONVERY LOW
P/S0.73.3
P/CFO10.116.1
P/FCF155.121.2
P/E-4.324.5
STABILITYPOOR
Debt/Equity1.380.21
Cash/Assets0.020.07

QDEL Stock

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
QDEL Return139%-25%-37%-14%-40%-33%-63%
Peers Return51%23%-41%33%-17%-15%4%
S&P 500 Return16%27%-19%24%23%14%106%

Monthly Win Rates [3]
QDEL Win Rate75%50%42%50%58%33% 
Peers Win Rate63%62%40%57%42%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
QDEL Max Drawdown-3%-42%-50%-32%-59%-49% 
Peers Max Drawdown-29%-8%-54%-9%-24%-29% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ABT, OSUR, WST, COO, ALGN. See QDEL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/22/2025 (YTD)

How Low Can It Go

Unique KeyEventQDELS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-77.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven336.7%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-49.7%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven98.7%51.3%
2020 Covid PandemicTime to BreakevenTime to BreakevenNot Fully Recovered days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-42.1%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven72.6%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven380 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-62.0%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven163.1%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1390 days1480 days

Compare to ABT, OSUR, WST, COO, ALGN


In The Past

QuidelOrtho's stock fell -77.1% during the 2022 Inflation Shock from a high on 2/1/2021. A -77.1% loss requires a 336.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About QuidelOrtho (QDEL)

Better Bets than QuidelOrtho (QDEL)

 QDELBetter Performance than QDEL
MetricValueIndustry (Health Care Supplies)
Rev Chg LTM-3.3%WST (2.9%), COO (6.4%), ALGN (0.6%), MMSI (8.2%), LNTH (5.7%)
Rev Chg 3Y Avg0.3%WST (0.4%), COO (7.9%), MMSI (8.0%), LNTH (34.3%), ICUI (10.7%)
Op Mgn LTM4.2%WST (21.0%), COO (18.3%), ALGN (16.1%), MMSI (11.7%), LNTH (28.9%)
CFO/Rev LTM7.3%WST (22.9%), COO (20.2%), ALGN (18.4%), MMSI (16.2%), LNTH (34.7%)
FCF/Rev LTM0.5%WST (11.6%), COO (10.2%), ALGN (15.9%), MMSI (12.8%), LNTH (31.1%)
Total Yield-23.1%WST (2.6%), COO (2.7%), ALGN (4.4%), MMSI (2.5%), LNTH (6.9%)
 QDELBetter Performance than QDEL
MetricValueAll Other Sectors
Rev Chg LTM-3.3%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.3%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM4.2%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM7.3%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM0.5%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-23.1%NVDA (2.0%), MSFT (3.3%), AAPL (3.0%), GOOGL (4.1%), AMZN (3.0%)
null

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1QuidelOrtho Stock Up 10%, Buy Or Wait?Return 
2Better Bet Than QDEL Stock: Pay Less Than QuidelOrtho To Get More From AVNS, HAE Actionable 
3Day 8 of Loss Streak for QuidelOrtho Stock with -20% Return (vs. -43% YTD) [7/21/2025]Notification 
4QDEL Dip Buy Analysis  
5QuidelOrtho Earnings Notes  
6QuidelOrtho Market PriceMarket Price 
7QuidelOrtho During 2008 Recession vs. 2022 Inflation Shock: QDEL Stock Has 811% Upside If It Recovers To Pre-Inflation Shock Levels Actionable 
8QuidelOrtho Total Shareholder Return (TSR): -40.0% in 2024 and -31.0% 3-yr compounded annual returns (above peer average)  
9QuidelOrtho (QDEL) Operating Cash Flow ComparisonFinancials 
10QuidelOrtho (QDEL) Net Income ComparisonFinancials 
11ARTICLES  
12Better Bet Than QuidelOrtho Stock: Pay Less To Get More From HAE, AVNS August 21st, 2025
13QDEL Stock Down -20% after 8-Day Loss Streak July 22nd, 2025
14QDEL Dropped 16% In A Week. Bigger Declines Have Followed Similar Moves. July 19th, 2025
15Down 15% In A Month, Will QuidelOrtho Stock Rebound? August 9th, 2022
16Labcorp, Quidel: Omicron Brings Covid Testing Stocks Back In Focus December 20th, 2021
Title
0DASHBOARDS
1Better Bet Than QuidelOrtho Stock: Pay Less To Get More From HAE, AVNS
2QDEL Stock Down -20% after 8-Day Loss Streak
3QDEL Dropped 16% In A Week. Bigger Declines Have Followed Similar Moves.
4Down 15% In A Month, Will QuidelOrtho Stock Rebound?
5Labcorp, Quidel: Omicron Brings Covid Testing Stocks Back In Focus
6ARTICLES
7QuidelOrtho Stock Up 10%, Buy Or Wait?
8Better Bet Than QDEL Stock: Pay Less Than QuidelOrtho To Get More From AVNS, HAE 
9Day 8 of Loss Streak for QuidelOrtho Stock with -20% Return (vs. -43% YTD) [7/21/2025]
10QDEL Dip Buy Analysis
11QuidelOrtho Earnings Notes
12QuidelOrtho Market Price
13QuidelOrtho During 2008 Recession vs. 2022 Inflation Shock: QDEL Stock Has 811% Upside If It Recovers To Pre-Inflation Shock Levels 
14QuidelOrtho Total Shareholder Return (TSR): -40.0% in 2024 and -31.0% 3-yr compounded annual returns (above peer average)
15QuidelOrtho (QDEL) Operating Cash Flow Comparison
16QuidelOrtho (QDEL) Net Income Comparison

Trade Ideas

Select past ideas related to QDEL. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%
QDEL_9302022_Dip_Buyer_High_CFO_Margins_ExInd_DE09302022QDELQuidelOrthoDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		24.6%2.2%-5.6%
QDEL_1312022_Dip_Buyer_High_CFO_Margins_ExInd_DE01312022QDELQuidelOrthoDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-1.4%-17.2%-34.7%
QDEL_12312020_Dip_Buyer_ValueBuy12312020QDELQuidelOrthoDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-28.4%-24.9%-42.1%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		0.4%0.4%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		3.0%3.0%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		6.3%6.3%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		16.1%16.1%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		-0.9%-0.9%-8.0%
QDEL_9302022_Dip_Buyer_High_CFO_Margins_ExInd_DE09302022QDELQuidelOrthoDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		24.6%2.2%-5.6%
QDEL_1312022_Dip_Buyer_High_CFO_Margins_ExInd_DE01312022QDELQuidelOrthoDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-1.4%-17.2%-34.7%
QDEL_12312020_Dip_Buyer_ValueBuy12312020QDELQuidelOrthoDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		-28.4%-24.9%-42.1%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1WOLFWolfspeed1366.7%342.6%
2QUREuniQure338.6%239.2%
3PRAXPraxis Precision Medicines279.5%139.6%
4LACLithium Americas117.9%125.3%
5CLPTClearPoint Neuro99.8%57.9%
6NVTSNavitas Semiconductor97.7%281.1%
7UAMYUnited States Antimony79.6%640.7%
8ORKAOruka Therapeutics71.3%37.4%
9GRALGRAIL69.8%346.8%
10TSHATaysha Gene Therapies69.2%185.5%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1SOCSable Offshore-51.7%-48.4%
2FLYFirefly Aerospace-37.4% 
3UPWheels Up Experience-37.0%-12.1%
4VGVenture Global-34.5% 
5PSIXPower Solutions International-33.0%160.7%
6ALABAstera Labs-32.7%16.9%
7FWRDForward Air-30.6%-41.0%
8QUBTQuantum Computing-30.5%-10.2%
9AEHRAehr Test Systems-29.6%42.4%
10TIPTTiptree-29.0%-15.1%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1PRAXPraxis Precision Medicines221.6%139.6%
2VICRVicor49.6%77.5%
3CCOClear Channel Outdoor41.2%40.1%
4CELCCelcuity40.0%435.1%
5WGOWinnebago Industries34.9%-11.6%
6BALYBallys27.4%-2.4%
7TFINTriumph Financial27.3%-32.9%
8SIONSionna Therapeutics25.8% 
9LVWRLiveWire24.4%29.1%
10PMIPicard Medical24.4%20804.8%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1BITFBitfarms-39.1%164.4%
2QBTSD-Wave Quantum-39.1%224.9%
3RGTIRigetti Computing-36.0%136.3%
4SMRNuScale Power-35.0%93.6%
5RCATRed Cat-31.9%-22.3%
6BKSYBlackSky Technology-31.3%101.3%
7OKLOOklo-30.0%465.8%
8QUBTQuantum Computing-30.0%-10.2%
9SESSES AI-29.9%13.2%
10ASPIASP Isotopes-29.4%96.7%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for QuidelOrtho

Financials

QDELABTOSURWSTCOOALGNMedian
NameQuidelOr.Abbott L.OraSure .West Pha.Cooper C.Align Te. 
Mkt Price29.80127.952.87277.0074.45135.58101.20
Mkt Cap2.0223.10.220.014.89.812.3
Rev LTM2,74243,1091392,9604,0463,9653,463
Op Inc LTM1147,515-54622741638630
FCF LTM136,775-20344412632378
FCF 3Y Avg-165,97238366274549320
CFO LTM2009,037-17677816731704
CFO 3Y Avg1818,13046712665706685

Growth & Margins

QDELABTOSURWSTCOOALGNMedian
NameQuidelOr.Abbott L.OraSure .West Pha.Cooper C.Align Te. 
Rev Chg LTM-3.3%5.9%-49.4%2.9%6.4%0.6%1.7%
Rev Chg 3Y Avg0.3%-1.5%-3.8%0.4%7.9%-0.1%0.1%
Rev Chg Q-3.6%7.4%-42.5%9.2%5.7%-1.6%2.1%
QoQ Delta Rev Chg LTM-0.8%1.8%-14.3%2.2%1.4%-0.4%0.5%
Op Mgn LTM4.2%17.4%-39.0%21.0%18.3%16.1%16.8%
Op Mgn 3Y Avg6.1%16.2%-7.8%22.2%16.5%16.3%16.2%
QoQ Delta Op Mgn LTM1.0%0.6%-15.2%0.5%-0.7%-0.3%0.1%
CFO/Rev LTM7.3%21.0%-12.4%22.9%20.2%18.4%19.3%
CFO/Rev 3Y Avg6.1%19.6%11.5%24.6%17.5%18.3%17.9%
FCF/Rev LTM0.5%15.7%-14.5%11.6%10.2%15.9%10.9%
FCF/Rev 3Y Avg-0.7%14.4%8.9%12.6%7.2%14.2%10.8%

Valuation

QDELABTOSURWSTCOOALGNMedian
NameQuidelOr.Abbott L.OraSure .West Pha.Cooper C.Align Te. 
Mkt Cap2.0223.10.220.014.89.812.3
P/S0.75.21.56.83.72.53.1
P/EBIT-8.826.5-4.033.520.615.418.0
P/E-4.316.0-4.241.036.422.519.2
P/CFO10.124.7-12.529.618.213.515.8
Total Yield-23.1%8.0%-23.9%2.6%2.7%4.4%2.7%
Dividend Yield0.0%1.8%0.0%0.2%0.0%0.0%0.0%
FCF Yield 3Y Avg-1.7%3.0%10.4%1.7%1.7%3.0%2.3%
D/E1.40.10.10.00.20.00.1
Net D/E1.30.0-1.0-0.00.2-0.10.0

Returns

QDELABTOSURWSTCOOALGNMedian
NameQuidelOr.Abbott L.OraSure .West Pha.Cooper C.Align Te. 
1M Rtn4.7%-5.9%-13.6%9.8%9.5%3.4%4.0%
3M Rtn12.0%2.1%-13.0%21.9%1.5%-33.6%1.8%
6M Rtn15.8%-0.6%-4.3%27.2%-7.9%-23.5%-2.5%
12M Rtn-24.8%12.3%-29.8%-3.0%-29.7%-35.7%-27.2%
3Y Rtn-62.2%42.7%-26.0%19.8%14.6%-34.7%-5.7%
1M Excs Rtn8.0%-6.1%-13.1%9.8%9.7%4.5%6.2%
3M Excs Rtn7.9%-3.0%-18.8%-6.0%-4.4%-38.2%-5.2%
6M Excs Rtn-8.8%-25.2%-29.0%2.6%-32.5%-48.1%-27.1%
12M Excs Rtn-41.2%-5.0%-45.1%-19.5%-45.5%-52.5%-43.2%
3Y Excs Rtn-143.6%-51.1%-108.7%-72.9%-67.6%-118.0%-90.8%

Comparison Analyses

Financials

$ Mil | FY: 12/292025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/29/20253/30/202512/29/20249/29/20246/30/20243/31/202412/31/202310/1/20237/2/20234/2/20231/1/202310/2/2022
Filing Date8/6/20255/8/20252/27/202511/8/20248/1/20245/9/20242/29/202411/2/20238/9/20235/4/20232/23/202311/4/2022
Key Financials Quarterly            
Total Revenue614693708727637711743744665846866784
Ebitda-76141131341-1,63815214495216195164
Operating Income-2491552-3087455-212911683
Net Income-255-13-178-20-148-1,7067-13-53493019
EPS-3.77-0.19-2.28-0.30-2.20-25.500.10-0.19-0.800.730.460.29
Key Financials TTM            
Total Revenue TTM2,7422,7652,7832,8182,8352,8632,9983,1223,1623,1103,2663,036
Ebitda TTM211288-1,490-1,350-1,340-1,2466076506696741,0941,290
Operating Income TTM11486461051081362562983264889821,251
Net Income TTM-466-359-2,052-1,867-1,859-1,765-101345118549810
Growth Rates Quarterly            
Total Revenue Growth-3.6%-2.6%-4.7%-2.3%-4.2%-16.0%-14.3%-5.1%8.4%-15.6%36.0%53.7%
EBITDA Growth-7740.0%108.6%-91.4%-7.2%-98.9%-859.6%-21.8%-12.1%-4.3%-66.1%-50.1%-44.3%
Operating Income Growth93.9%472.9%-79.6%-5.8%-1250.0%-93.4%-35.7%-33.9%-101.4%-79.3%-69.9%-70.5%
Net Income Growth-72.9%99.3%-2648.6%-56.7%-177.6%-3595.9%-76.9%-166.1%-375.6%-89.8%-89.6%-91.1%
Margins Quarterly            
EBITDA Margin-12.4%20.3%1.9%18.4%0.2%-230.3%20.5%19.4%14.3%25.5%22.5%20.9%
Operating Income Margin-0.3%7.0%2.1%7.1%-4.7%1.2%10.0%7.4%-0.3%15.3%13.4%10.6%
Net Income Margin-41.6%-1.8%-25.2%-2.7%-23.2%-239.9%0.9%-1.7%-8.0%5.8%3.5%2.4%
Cash & Debt            
Total Cash1521279814410778167193224397345264
Total Debt2,7932,6942,6812,7562,7712,6132,6142,6702,7232,7962,8492,875
Net Debt / (Cash)2,6412,5672,5832,6122,6642,5342,4472,4772,5002,4002,5042,611
Cash Flows Quarterly            
FCF from Operations-476664118-98-18042-31189169-10
Cash Flows TTM            
FCF from Operations TTM2001498310023912803693185738851,037
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-07-0-0-0-074
Return on Invested Capital (ROIC) Quarterly            
ROIC-0.1%3.6%1.1%2.6%-2.0%0.6%5.7%3.4%-0.1%8.2%6.5%3.9%
Return on Invested Capital (ROIC) TTM            
ROIC TTM2.0%1.6%0.8%1.8%1.8%2.4%1.7%3.5%4.1%6.4%14.0%18.1%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Labs1,42582045  
Point of Care8921,9551,453  
Immunohematology512297   
Donor Screening13697   
Molecular Diagnostics329720022322
Transfusion Medicine  0  
Cardiometabolic Immunoassay   243267
Rapid Immunoassay   1,145192
Specialized Diagnostic Solutions   5155
Total2,9983,2661,6991,662535


Price Behavior

QDEL Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta3.612.732.991.681.511.11
Up Beta9.516.045.741.231.231.16
Down Beta0.130.170.421.861.591.10
Up Capture236%303%226%198%160%47%
Bmk +ve Days13233574144420
Stock +ve Days10192653107357
Down Capture388%132%300%202%146%106%
Bmk -ve Days8192952107330
Stock -ve Days11233772142388

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9302025
Short Interest: Shares Quantity8,696,201
Short Interest: % Change Since 91520256.7%
Average Daily Volume1,328,651
Days-to-Cover Short Interest6.55
Basic Shares Quantity67,700,000
Short % of Basic Shares12.8%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/5/2025-1.0%6.4%17.4%
5/7/202541.0%29.8%14.2%
2/12/20254.3%2.7%-9.6%
11/7/202412.6%0.3%4.3%
7/31/20246.9%0.8%10.9%
5/8/20242.2%5.3%-2.4%
2/13/2024-32.2%-25.9%-28.9%
11/1/20233.7%-0.3%14.4%
...
SUMMARY STATS   
# Positive776
# Negative667
Median Positive5.7%2.9%12.6%
Median Negative-5.8%-7.8%-8.0%
Max Positive41.0%29.8%17.4%
Max Negative-32.2%-25.9%-28.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025806202510-Q 6/29/2025
3312025508202510-Q 3/30/2025
12312024227202510-K 12/29/2024
93020241108202410-Q 9/29/2024
6302024801202410-Q 6/30/2024
3312024509202410-Q 3/31/2024
12312023229202410-K 12/31/2023
93020231102202310-Q 10/1/2023
6302023809202310-Q 7/2/2023
3312023504202310-Q 4/2/2023
12312022223202310-K 1/1/2023
93020221104202210-Q 10/2/2022
6302022805202210-Q 7/3/2022
3312022505202210-Q 3/31/2022
12312021218202210-K 12/31/2021
93020211105202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Blaser Brian J.President and CEO12132024Buy41.426,033249,878249,878Form
1Carlyle Group Inc.11212024Sell35.318,260,183291,700,102 Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.